Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
23
BOVNF Quote, Financials, Valuation and Earnings
Last price:
$4.70
Seasonality move
:
-10.76%
Day range:
$4.70 - $4.70
52-week range:
$4.70 - $4.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
84.18x
P/B ratio:
3.11x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$309.3M
Revenue:
$6.7M
EPS (TTM):
-$0.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BOVNF
BioInvent International AB
|
-- | -- | -- | -- | -- |
|
BRCTF
BioArctic AB
|
-- | -- | -- | -- | -- |
|
CAMRF
Camurus AB
|
-- | -- | -- | -- | -- |
|
HNSBF
Hansa Biopharma AB
|
-- | -- | -- | -- | -- |
|
NEVPF
Abliva AB
|
-- | -- | -- | -- | -- |
|
ONPPF
Oncopeptides AB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BOVNF
BioInvent International AB
|
$4.70 | -- | $309.3M | -- | $0.00 | 0% | 84.18x |
|
BRCTF
BioArctic AB
|
$19.32 | -- | $1.7B | -- | $0.00 | 0% | 107.08x |
|
CAMRF
Camurus AB
|
$50.97 | -- | $3B | 119.31x | $0.00 | 0% | 18.70x |
|
HNSBF
Hansa Biopharma AB
|
$3.00 | -- | $196.8M | -- | $0.00 | 0% | 9.81x |
|
NEVPF
Abliva AB
|
$0.04 | -- | $58M | -- | $0.00 | 0% | -- |
|
ONPPF
Oncopeptides AB
|
$0.27 | -- | $24M | -- | $0.00 | 0% | 8.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BOVNF
BioInvent International AB
|
-- | 0.000 | -- | 13.16x |
|
BRCTF
BioArctic AB
|
-- | 1.787 | -- | 5.10x |
|
CAMRF
Camurus AB
|
-- | 0.000 | -- | 7.91x |
|
HNSBF
Hansa Biopharma AB
|
151.36% | -0.207 | 48.65% | 2.44x |
|
NEVPF
Abliva AB
|
-- | -11.572 | -- | -- |
|
ONPPF
Oncopeptides AB
|
-- | -1.624 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BOVNF
BioInvent International AB
|
-- | -$10.3M | -33.69% | -33.69% | -839.44% | -$10M |
|
BRCTF
BioArctic AB
|
$6.6M | -$2.5M | -23.03% | -23.03% | -24.9% | -$8.3M |
|
CAMRF
Camurus AB
|
$43M | $13.7M | 11.41% | 11.41% | 34.52% | $14.2M |
|
HNSBF
Hansa Biopharma AB
|
$3.6M | -$11.3M | -95.02% | -- | -240.28% | -$15.3M |
|
NEVPF
Abliva AB
|
-- | -$1.9M | -- | -- | -- | -$3.8M |
|
ONPPF
Oncopeptides AB
|
-- | -- | -- | -- | -- | -- |
BioInvent International AB vs. Competitors
-
Which has Higher Returns BOVNF or BRCTF?
BioArctic AB has a net margin of -761.85% compared to BioInvent International AB's net margin of -25.62%. BioInvent International AB's return on equity of -33.69% beat BioArctic AB's return on equity of -23.03%.
Company Gross Margin Earnings Per Share Invested Capital BOVNFBioInvent International AB-- -$0.14 $99.5M BRCTFBioArctic AB89.45% -$0.02 $91.1M -
What do Analysts Say About BOVNF or BRCTF?
BioInvent International AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioInvent International AB has higher upside potential than BioArctic AB, analysts believe BioInvent International AB is more attractive than BioArctic AB.
Company Buy Ratings Hold Ratings Sell Ratings BOVNFBioInvent International AB0 0 0 BRCTFBioArctic AB0 0 0 -
Is BOVNF or BRCTF More Risky?
BioInvent International AB has a beta of 0.697, which suggesting that the stock is 30.276% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BOVNF or BRCTF?
BioInvent International AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioInvent International AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOVNF or BRCTF?
BioInvent International AB quarterly revenues are $1.2M, which are smaller than BioArctic AB quarterly revenues of $7.4M. BioInvent International AB's net income of -$9.4M is lower than BioArctic AB's net income of -$1.9M. Notably, BioInvent International AB's price-to-earnings ratio is -- while BioArctic AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioInvent International AB is 84.18x versus 107.08x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOVNFBioInvent International AB84.18x -- $1.2M -$9.4M BRCTFBioArctic AB107.08x -- $7.4M -$1.9M
-
Which has Higher Returns BOVNF or CAMRF?
Camurus AB has a net margin of -761.85% compared to BioInvent International AB's net margin of 26.97%. BioInvent International AB's return on equity of -33.69% beat Camurus AB's return on equity of 11.41%.
Company Gross Margin Earnings Per Share Invested Capital BOVNFBioInvent International AB-- -$0.14 $99.5M CAMRFCamurus AB93.01% $0.21 $308.7M -
What do Analysts Say About BOVNF or CAMRF?
BioInvent International AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioInvent International AB has higher upside potential than Camurus AB, analysts believe BioInvent International AB is more attractive than Camurus AB.
Company Buy Ratings Hold Ratings Sell Ratings BOVNFBioInvent International AB0 0 0 CAMRFCamurus AB0 0 0 -
Is BOVNF or CAMRF More Risky?
BioInvent International AB has a beta of 0.697, which suggesting that the stock is 30.276% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BOVNF or CAMRF?
BioInvent International AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioInvent International AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOVNF or CAMRF?
BioInvent International AB quarterly revenues are $1.2M, which are smaller than Camurus AB quarterly revenues of $46.2M. BioInvent International AB's net income of -$9.4M is lower than Camurus AB's net income of $12.5M. Notably, BioInvent International AB's price-to-earnings ratio is -- while Camurus AB's PE ratio is 119.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioInvent International AB is 84.18x versus 18.70x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOVNFBioInvent International AB84.18x -- $1.2M -$9.4M CAMRFCamurus AB18.70x 119.31x $46.2M $12.5M
-
Which has Higher Returns BOVNF or HNSBF?
Hansa Biopharma AB has a net margin of -761.85% compared to BioInvent International AB's net margin of -213.29%. BioInvent International AB's return on equity of -33.69% beat Hansa Biopharma AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOVNFBioInvent International AB-- -$0.14 $99.5M HNSBFHansa Biopharma AB76.62% -$0.15 $61.8M -
What do Analysts Say About BOVNF or HNSBF?
BioInvent International AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioInvent International AB has higher upside potential than Hansa Biopharma AB, analysts believe BioInvent International AB is more attractive than Hansa Biopharma AB.
Company Buy Ratings Hold Ratings Sell Ratings BOVNFBioInvent International AB0 0 0 HNSBFHansa Biopharma AB0 0 0 -
Is BOVNF or HNSBF More Risky?
BioInvent International AB has a beta of 0.697, which suggesting that the stock is 30.276% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.431%.
-
Which is a Better Dividend Stock BOVNF or HNSBF?
BioInvent International AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioInvent International AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOVNF or HNSBF?
BioInvent International AB quarterly revenues are $1.2M, which are smaller than Hansa Biopharma AB quarterly revenues of $4.7M. BioInvent International AB's net income of -$9.4M is higher than Hansa Biopharma AB's net income of -$10M. Notably, BioInvent International AB's price-to-earnings ratio is -- while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioInvent International AB is 84.18x versus 9.81x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOVNFBioInvent International AB84.18x -- $1.2M -$9.4M HNSBFHansa Biopharma AB9.81x -- $4.7M -$10M
-
Which has Higher Returns BOVNF or NEVPF?
Abliva AB has a net margin of -761.85% compared to BioInvent International AB's net margin of --. BioInvent International AB's return on equity of -33.69% beat Abliva AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOVNFBioInvent International AB-- -$0.14 $99.5M NEVPFAbliva AB-- -$0.00 -- -
What do Analysts Say About BOVNF or NEVPF?
BioInvent International AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Abliva AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioInvent International AB has higher upside potential than Abliva AB, analysts believe BioInvent International AB is more attractive than Abliva AB.
Company Buy Ratings Hold Ratings Sell Ratings BOVNFBioInvent International AB0 0 0 NEVPFAbliva AB0 0 0 -
Is BOVNF or NEVPF More Risky?
BioInvent International AB has a beta of 0.697, which suggesting that the stock is 30.276% less volatile than S&P 500. In comparison Abliva AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BOVNF or NEVPF?
BioInvent International AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abliva AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioInvent International AB pays -- of its earnings as a dividend. Abliva AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOVNF or NEVPF?
BioInvent International AB quarterly revenues are $1.2M, which are larger than Abliva AB quarterly revenues of --. BioInvent International AB's net income of -$9.4M is lower than Abliva AB's net income of -$1.9M. Notably, BioInvent International AB's price-to-earnings ratio is -- while Abliva AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioInvent International AB is 84.18x versus -- for Abliva AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOVNFBioInvent International AB84.18x -- $1.2M -$9.4M NEVPFAbliva AB-- -- -- -$1.9M
-
Which has Higher Returns BOVNF or ONPPF?
Oncopeptides AB has a net margin of -761.85% compared to BioInvent International AB's net margin of --. BioInvent International AB's return on equity of -33.69% beat Oncopeptides AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOVNFBioInvent International AB-- -$0.14 $99.5M ONPPFOncopeptides AB-- -- -- -
What do Analysts Say About BOVNF or ONPPF?
BioInvent International AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncopeptides AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioInvent International AB has higher upside potential than Oncopeptides AB, analysts believe BioInvent International AB is more attractive than Oncopeptides AB.
Company Buy Ratings Hold Ratings Sell Ratings BOVNFBioInvent International AB0 0 0 ONPPFOncopeptides AB0 0 0 -
Is BOVNF or ONPPF More Risky?
BioInvent International AB has a beta of 0.697, which suggesting that the stock is 30.276% less volatile than S&P 500. In comparison Oncopeptides AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BOVNF or ONPPF?
BioInvent International AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncopeptides AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioInvent International AB pays -- of its earnings as a dividend. Oncopeptides AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOVNF or ONPPF?
BioInvent International AB quarterly revenues are $1.2M, which are larger than Oncopeptides AB quarterly revenues of --. BioInvent International AB's net income of -$9.4M is higher than Oncopeptides AB's net income of --. Notably, BioInvent International AB's price-to-earnings ratio is -- while Oncopeptides AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioInvent International AB is 84.18x versus 8.28x for Oncopeptides AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOVNFBioInvent International AB84.18x -- $1.2M -$9.4M ONPPFOncopeptides AB8.28x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is up 22.25% over the past day.
Buy
69
UNF alert for Jan 8
UniFirst [UNF] is up 20.59% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 19.13% over the past day.
